Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 26957559.
- Also identified by DOI 10.1158/1078-0432.CCR-16-0169 and PMC identifier 4940186.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Blockade of the PD-1 axis has emerged as an effective anticancer immunotherapy against various tumor types. Diverse studies have identified biomarkers associated with response to these therapies. However, the clinical use of such tests is limited by their variable performance and restricted understanding of their biologic significance. Clin Cancer Res; 22(9); 2102-4. ©2016 AACRSee related article by Ock et al., p. 2261.
Medical subject headings
- Biomarkers, Tumor
- Neoplasms
- Programmed Cell Death 1 Receptor